An 80-year-old woman presented with new-onset hazy vision and glare for 5 months after starting netarsudil for severe primary open-angle glaucoma. She was noted to have corneal verticillata in both eyes (Figure) and conjunctival hyperemia but no corneal edema. Although the visual acuity remained stable at her baseline of 20/25 OD and 20/20 OS, there were no other findings to explain her symptoms, and her symptoms began to improve just 1 week after discontinuing netarsudil. Netarsudil ophthalmic solution, 0.02%, is a rho-kinase inhibitor used to lower intraocular pressure (IOP) in open-angle glaucoma, and corneal verticillata are a known adverse effect.1 In the Rho-Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) trials, vortex keratopathy occurred in up to 26% of patients and had no visual relevance.2,3 We present our case to make clinicians aware that netarsudil can be associated with corneal changes that may be symptomatic, as in this patient.